Equity Profile

CTNM

Contineum Therapeutics, Inc.

Health CarePharmaceuticals$546.6M

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Contineum Therapeutics, Inc. is a pharmaceutical company focused on developing innovative therapies for various health conditions....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health. Investors will be looking for signs of improvement or worsening losses.

N/A

Revenue Growth

Revenue growth is crucial for assessing the company's ability to expand its market presence and sustain operations, especially in the competitive pharmaceutical industry.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

CTNM Q2-2026 Earnings Preview

Context

Company Snapshot

Contineum Therapeutics, Inc. is a pharmaceutical company focused on developing innovative therapies for various health conditions. With a market cap of $1 billion, it operates in the healthcare sector, which is increasingly important as the demand for effective treatments continues to grow.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+1.76%

Avg Stock Reaction

-0.13%

Last Quarter Recap

In Q1-2026, Contineum reported an EPS of -$0.39, which was better than the expected -$0.55, resulting in a positive surprise of nearly 30%. Following the announcement, the stock rose by 1.70% the next day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts are uncertain about the upcoming earnings report due to a lack of analyst estimates and management guidance. Investors are keen to see if the company can continue to beat EPS expectations.

Bull Case

If Contineum can report a smaller loss than expected and show signs of revenue growth, it could boost investor confidence and lead to a significant stock price increase.

Bear Case

If the company fails to meet expectations or reports a larger loss, it may lead to a decline in stock price as investors reassess the company's viability.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026, and will it show a continued improvement over the previous quarter?

The EPS figure is crucial for assessing the company's profitability trajectory and will heavily influence investor sentiment.

What insights can be shared regarding revenue growth or any new product developments?

Understanding revenue trends and product pipeline updates will help gauge the company's future potential and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Contineum's potential for a significant EPS improvement this quarter, given its recent trend of beating expectations.

Supporting Evidence

The company has a history of surprising positively on EPS, with a 63% beat rate over the last eight quarters.

Options pricing suggests a much larger move than historical averages, indicating that traders expect a significant reaction.

Key Risk

If the EPS comes in better than -$0.39, it could challenge the current cautious sentiment and lead to a reassessment of the company's outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter, the focus will be on whether the company can maintain its recent trend of beating EPS expectations and show signs of revenue growth.

Bull Confirmed If

A reported EPS loss of less than -$0.39 would confirm the bull case and suggest improving financial health.

Bear Confirmed If

An EPS loss greater than -$0.39 would confirm the bear case and indicate ongoing financial struggles.

Pre-Earnings Positioning

Options Market

Implied Move

±25.8%

Historical Avg

±4.0%

Pricing rich

The options market is pricing in a significant move of nearly 26%, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±25.8% while CTNM has averaged ±4.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.3%

30d HV

58.6%

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Contineum beats expectations, history suggests the stock could rise by around 3.1% on the first day, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations but management is cautious, the stock may experience minimal movement as investors reassess future growth prospects.

Miss

If the company misses expectations, history suggests a potential decline of about 0.1%, leading to increased scrutiny of its financial health.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product pipeline and expected launch timelines.
2Details on cost management strategies and their impact on future profitability.
3Insights into market conditions and competitive landscape affecting revenue.
4Management's commentary on future guidance and growth strategies.
5Responses to analyst questions regarding recent performance trends.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Contineum Therapeutics, Inc. is a pharmaceutical company focused on developing innovative therapies for various health conditions....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health. Investors will be looking for signs of improvement or worsening losses.

N/A

Revenue Growth

Revenue growth is crucial for assessing the company's ability to expand its market presence and sustain operations, especially in the competitive pharmaceutical industry.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

CTNM Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+1.76%

Avg Stock Reaction

-0.13%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts are uncertain about the upcoming earnings report due to a lack of analyst estimates and management guidance. Investors are keen to see if the company can continue to beat EPS expectations.

Bull Case

If Contineum can report a smaller loss than expected and show signs of revenue growth, it could boost investor confidence and lead to a significant stock price increase.

Bear Case

If the company fails to meet expectations or reports a larger loss, it may lead to a decline in stock price as investors reassess the company's viability.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026, and will it show a continued improvement over the previous quarter?

The EPS figure is crucial for assessing the company's profitability trajectory and will heavily influence investor sentiment.

What insights can be shared regarding revenue growth or any new product developments?

Understanding revenue trends and product pipeline updates will help gauge the company's future potential and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Contineum's potential for a significant EPS improvement this quarter, given its recent trend of beating expectations.

Supporting Evidence

The company has a history of surprising positively on EPS, with a 63% beat rate over the last eight quarters.

Options pricing suggests a much larger move than historical averages, indicating that traders expect a significant reaction.

Key Risk

If the EPS comes in better than -$0.39, it could challenge the current cautious sentiment and lead to a reassessment of the company's outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter, the focus will be on whether the company can maintain its recent trend of beating EPS expectations and show signs of revenue growth.

Bull Confirmed If

A reported EPS loss of less than -$0.39 would confirm the bull case and suggest improving financial health.

Bear Confirmed If

An EPS loss greater than -$0.39 would confirm the bear case and indicate ongoing financial struggles.

Pre-Earnings Positioning

Options Market

Implied Move

±25.8%

Historical Avg

±4.0%

Pricing rich

The options market is pricing in a significant move of nearly 26%, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±25.8% while CTNM has averaged ±4.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.3%

30d HV

58.6%

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Contineum beats expectations, history suggests the stock could rise by around 3.1% on the first day, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations but management is cautious, the stock may experience minimal movement as investors reassess future growth prospects.

Miss

If the company misses expectations, history suggests a potential decline of about 0.1%, leading to increased scrutiny of its financial health.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product pipeline and expected launch timelines.
2Details on cost management strategies and their impact on future profitability.
3Insights into market conditions and competitive landscape affecting revenue.
4Management's commentary on future guidance and growth strategies.
5Responses to analyst questions regarding recent performance trends.